Six years after the proband's initial presentation, a 204‐gene combined neuromuscular and cardiomyopathy panel from a second commercial laboratory identified a partial deletion of TTN (exons 346‐362), interpreted as likely pathogenic. This evidence concerns the gene TTN and cardiomyopathy.